Shares of Sun Pharmaceutical Industries Ltd were dented on Indian bourses after investors appeared concerned that the US FDA's decision to rescind a previous approval for its R&D arm's new drug application (NDA) for Elepsia XR (levetiracetam extended-release tablets) implied more than met the eye.
Sun Pharma Advanced Research Company Ltd (SPARC) is the listed R&D spin-off of Sun Pharma, which has been evaluating several...